Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,673.00
(
-0.64%
)
US TECH 100
24,016.40
(
-0.48%
)
Dow Jones
46,563.48
(
-0.91%
)
Brent Oil
105.25
(
4.57%
)
Bitcoin
71,298.37
(
-3.58%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 72295

Tuesday, 01/27/2009 9:47:14 PM

Tuesday, January 27, 2009 9:47:14 PM

Post# of 257253
Elvitegravir (via Quadro) and IDX899 are competing for the same slot: the addend to Truvada in first- and second-line HIV; however, there ought to be more than enough business to go around. For the sake of discussion, say Quadro eventually captures 50% of the Atripla market. This would still leave a huge market for a drug such as IDX899 that could supersede Sustiva in an updated version of Atripla consisting of Truvada plus an NNRTI.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now